Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial

Marty Francisco M.; Winston Drew J.; Chemaly Roy F.; Boeckh Michael J.; Mullane Kathlene M.; Shore Tsiporah B.; Papanicolaou Genovefa A.; Morrison Marion E.; Brundage Thomas M.; Mommeja-Marin Herve

首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial

【24h】

Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial

机译：brincidofovir用于预防CMV血清阳性患者的同种异体造血细胞移植（HCT）后的巨细胞病毒（CMV）：一项随机，双盲，安慰剂对照，平行组3期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2016年第1期|共1页
作者
Marty Francisco M.; Winston Drew J.; Chemaly Roy F.; Boeckh Michael J.; Mullane Kathlene M.; Shore Tsiporah B.; Papanicolaou Genovefa A.; Morrison Marion E.; Brundage Thomas M.; Mommeja-Marin Herve;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial [J] . Marty Francisco M., Winston Drew J., Chemaly Roy F., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：brincidofovir用于预防CMV血清阳性患者的同种异体造血细胞移植（HCT）后的巨细胞病毒（CMV）：一项随机，双盲，安慰剂对照，平行组3期试验
2. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation [J] . American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons . 2020,第6期

机译：可检测CMV DNA患者的结果，随机化在Letermovir的III期试验中预防同种异体造血细胞移植中的CMV感染
3. Clinical Outcome Associated with Cytomegalovirus (CMV) Infection/Disease in CMV-Seropositive Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation [J] . De latour Regis Peffault, Chevallier Patrice, Blaise Didier, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：同种异体造血干细胞移植后CMV-血清阳性成年患者CMV血清阳性成年患者患有患有巨细胞病毒（CMV）感染/疾病的临床结果
4. THE EFFECT OF INHIBITORY KILLER-CELL IG-LIKE RECEPTOR (IKIR) MATCHING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) [C] . David Senitzer, Joel Y. Sun, Arisa Oki, Clinical Histocompatibility Workshop. . 2009

机译：同种异体造血细胞移植（HCT）中抑制杀伤细胞IG样受体（IKIR）匹配的影响
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. 1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients [O] . Francisco M Marty, Per Ljungman, Roy F Chemaly, -1

机译：1730.接受可检测到的巨细胞病毒（CMV）DNA的患者在lettermovir（LET）预防CMV阳性异基因造血细胞移植（HCT）接受者的双盲安慰剂对照的3期试验中随机分组的结果
7. 1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients [O] . Francisco M Marty, Per Ljungman, Roy F Chemaly, 2018

机译：1730. 1730.在双盲，安慰剂对照相3试验中随机化的患者的患者的结果（Letermovir（Let）预防CMV-血清阳性同种异体造血 - 细胞移植（HCT）接受者

Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial

著录项

相似文献

相关主题

期刊订阅